edoxaban + Clopidogrel + Aspirin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral Arterial Disease
Conditions
Peripheral Arterial Disease
Trial Timeline
Feb 6, 2013 → Dec 3, 2014
NCT ID
NCT01802775About edoxaban + Clopidogrel + Aspirin
edoxaban + Clopidogrel + Aspirin is a phase 2 stage product being developed by Daiichi Sankyo for Peripheral Arterial Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01802775. Target conditions include Peripheral Arterial Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01802775 | Phase 2 | Completed |
Competing Products
20 competing products in Peripheral Arterial Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SON-080 | Sonnet BioTherapeutics | Phase 1/2 | 36 |
| LY3857210 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg | Yuhan | Approved | 85 |
| YHD1119 + Lyrica | Yuhan | Phase 1 | 33 |
| Anplag Tab. 100mg bid + Anplag Tab. 100mg tid | Yuhan | Approved | 85 |
| YHD1119 + Lyrica | Yuhan | Phase 1 | 33 |
| YHD1119 + Lyrica | Yuhan | Phase 3 | 77 |
| YHD1119 300mg + YHD1119 300mg | Yuhan | Phase 1 | 33 |
| DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule | Daiichi Sankyo | Phase 2 | 52 |
| DS-5565 + placebo | Daiichi Sankyo | Phase 3 | 77 |
| Mirogabalin + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo | Astellas Pharma | Phase 2 | 52 |
| Qutenza | Astellas Pharma | Pre-clinical | 23 |
| QUTENZA + Lidocaine + Tramadol | Astellas Pharma | Approved | 85 |
| Qutenza exposure | Astellas Pharma | Pre-clinical | 23 |
| QUTENZA | Astellas Pharma | Phase 3 | 77 |
| Qutenza + Pregabalin | Astellas Pharma | Approved | 85 |
| Capsaicin 8% + Placebo | Astellas Pharma | Phase 3 | 77 |